|
🐜
|
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
45 auth.
H. Wiendl,
R. Gold,
T. Berger,
T. Derfuss,
R. Linker,
M. Mäurer,
O. Aktas,
K. Baum,
M. Berghoff,
S. Bittner,
A. Chan,
A. Czapliński,
F. Deisenhammer,
Franziska Di Pauli,
R. D. Du Pasquier,
...
C. Enzinger,
E. Fertl,
A. Gass,
K. Gehring,
C. Gobbi,
N. Goebels,
M. Guger,
A. Haghikia,
H. Hartung,
F. Heidenreich,
O. Hoffmann,
B. Kallmann,
C. Kleinschnitz,
L. Klotz,
V. Leussink,
F. Leutmezer,
V. Limmroth,
J. Lünemann,
A. Lutterotti,
S. Meuth,
U. Meyding-Lamadé,
M. Plattén,
P. Rieckmann,
S. Schmidt,
H. Tumani,
F. Weber,
Martin S. Weber,
U. Zettl,
T. Ziemssen,
F. Zipp
|
7 |
2021 |
7
🐜
|
|
🐜
|
B Cell Depletion and SARS‐CoV‐2 Vaccine Responses in Neuroimmunologic Patients
22 auth.
B. Kornek,
F. Leutmezer,
P. Rommer,
M. Koblischke,
L. Schneider,
H. Haslacher,
R. Thalhammer,
F. Zimprich,
G. Zulehner,
G. Bsteh,
...
A. Dal-Bianco,
W. Rinner,
K. Zebenholzer,
I. Wimmer,
Anja Steinmaurer,
Marianne Graninger,
M. Mayer,
K. Roedl,
T. Berger,
S. Winkler,
J. Aberle,
S. Tobudic
|
5 |
2022 |
5
🐜
|
|
🐢
|
Real‐life clinical use of natalizumab and fingolimod in Austria
7 auth.
M. Guger,
C. Enzinger,
F. Leutmezer,
J. Kraus,
Stefan Kalcher,
E. Kvas,
...
T. Berger
|
4 |
2018 |
4
🐢
|
|
🐜
|
Extensive Brain Pathologic Alterations Detected with 7.0-T MR Spectroscopic Imaging Associated with Disability in Multiple Sclerosis.
16 auth.
E. Hečková,
A. Dal-Bianco,
Bernhard Strasser,
G. Hangel,
Alexandra Lipka,
S. Motyka,
Lukas Hingerl,
P. Rommer,
T. Berger,
P. Hnilicová,
...
E. Kantorová,
F. Leutmezer,
E. Kurča,
S. Gruber,
S. Trattnig,
W. Bogner
|
4 |
2022 |
4
🐜
|
|
🐜
|
Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease
24 auth.
E. Berger-Sieczkowski,
V. Endmayr,
Carmen Haider,
G. Ricken,
Philipp Jauk,
S. Macher,
W. Pirker,
B. Högl,
A. Heidbreder,
P. Schnider,
...
Eszter Bradley-Zechmeister,
S. Mariotto,
I. Koneczny,
Raphael Reinecke,
G. Kasprian,
Corinna Weber,
M. Bergmann,
I. Milenkovic,
T. Berger,
C. Gaig,
L. Sabater,
F. Graus,
E. Gelpí,
R. Höftberger
|
4 |
2023 |
4
🐜
|
|
🐢
|
Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study
15 auth.
G. Bsteh,
H. Assar,
C. Gradl,
Bettina Heschl,
M. Hiller,
Nik Krajnc,
Franziska Di Pauli,
H. Hegen,
G. Traxler,
F. Leutmezer,
...
P. Wipfler,
G. Zulehner,
M. Guger,
C. Enzinger,
T. Berger
|
4 |
2022 |
4
🐢
|
|
🐜
|
Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosis
19 auth.
Annika Hofmann,
Nik Krajnc,
A. Dal-Bianco,
Christian J. Riedl,
T. Zrzavy,
Celia Lerma-Martin,
G. Kasprian,
Claudia E. Weber,
Francesco Pezzini,
F. Leutmezer,
...
P. Rommer,
G. Bsteh,
M. Platten,
Achim Gass,
T. Berger,
P. Eisele,
R. Magliozzi,
Lucas Schirmer,
S. Hametner
|
3 |
2023 |
3
🐜
|
|
🐜
|
Impact of vaccination on COVID‐19 outcome in multiple sclerosis
45 auth.
G. Bsteh,
C. Gradl,
Bettina Heschl,
H. Hegen,
Franziska Di Pauli,
H. Assar,
F. Leutmezer,
G. Traxler,
Nik Krajnc,
G. Zulehner,
Maria‐Sophia Hiller,
P. Rommer,
P. Wipfler,
M. Guger,
C. Enzinger,
...
T. Berger,
Heidi Lemmerer,
G. Bsteh,
Doris Aigner,
H. Assar,
T. Berger,
K. Böck,
C. Bsteh,
Franziska Di Pauli,
C. Enzinger,
C. Gradl,
E. Gruber,
M. Guger,
H. Hegen,
Bettina Heschl,
M. Hiller,
B. Kornek,
F. Leutmezer,
Camillo Lex,
M. Mayr,
G. Morgenstern,
Dirk Oel,
P. Rommer,
P. Schnabl,
G. Schneider‐Koch,
G. Schrotter,
G. Traxler,
P. Wipfler,
G. Zulehner,
T. Zrzavy
|
3 |
2022 |
3
🐜
|
